NAFLD & NASH Pathophysiology: Mechanisms of Liver Fibrosis

Added:

The Lipotoxicity Hypothesis: Steatosis as a Protective Mechanism

While traditional models of NAFLD/NASH pathogenesis often view simple steatosis (fat accumulation) as the initial pathogenic step directly leading to injury, an important alternative perspective argues that triglyceride accumulation is actually a protective, buffering mechanism. According to the lipotoxicity hypothesis, the synthesis of inert triglycerides shields the liver from the toxic effects of free fatty acids (FFAs) and other reactive lipid species. Pathological progression to NASH and fibrosis occurs not because of steatosis itself, but when the liver's capacity to safely store fat as triglycerides is overwhelmed, leading to the accumulation of lipotoxic intermediates like diacylglycerols, ceramides, and free cholesterol. This perspective shifts the therapeutic and diagnostic focus away from merely reducing liver fat content toward targeting pathways that mitigate lipotoxic cellular stress, mitochondrial dysfunction, and inflammation directly, challenging the linear 'steatosis-to-fibrosis' paradigm.

Basic anatomy and histology of the liver, including the function of hepatocytes, hepatic stellate cells, and Kupffer cells.
The biochemical processes of lipid metabolism, specifically de novo lipogenesis, triglyceride synthesis, and beta-oxidation.
The pathophysiology of insulin resistance and its systemic metabolic consequences, such as metabolic syndrome and type 2 diabetes.
General cellular mechanisms of inflammation, oxidative stress, and the wound-healing response (fibrogenesis) in tissue injury.
Diagnostic and staging modalities for NAFLD/NASH, including non-invasive biomarkers (FIB-4), transient elastography (FibroScan), and liver biopsy.
Current and emerging pharmacotherapies for NASH, specifically targeting metabolic pathways, inflammation, and anti-fibrotic mechanisms.
The clinical management of advanced liver disease complications arising from NASH cirrhosis, such as portal hypertension and hepatocellular carcinoma (HCC).
Therapeutic lifestyle interventions, including the clinical impact of bariatric surgery and dietary strategies targeting the gut-liver axis.
133 views4likes17:15@fattyliverallianceOriginal Release: 2023-12-18

NAFLD/NASH progression begins with obesity-induced adipose tissue inflammation causing systemic insulin resistance, which triggers increased lipolysis releasing free fatty acids and de novo lipogenesis converting glucose to fatty acids, leading to hepatic lipid accumulation (steatosis); subsequent lipotoxicity injures hepatocytes through apoptosis, activating hepatic stellate cells to produce collagen and fibrosis, while genetic polymorphisms like PNPLA3 and HSD17B13 influence susceptibility and progression, ultimately resulting in significant mortality risk with cirrhosis carrying approximately 7.5% annual decompensation risk and increased hepatocellular carcinoma development.